Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...
As scientists grapple with the implications of a CRISPR-baby world, a new analysis took an unusual approach to analyzing the risks and benefits of germline editing. For one, it was completely inside a ...
Even as other researchers swarmed into the nascent field of CRISPR research, “Prashant and I were getting ... endeavoring to draw attention to the risks and the possibility of unforeseen outcomes. “We ...
Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...
Key risks with CRISPR have migrated over time from concern about achieving end points in its trials, to whether the FDA would approve a CRISPR-based treatment, to know how successful that ...
CRISPR stocks are high risk but hold potential for aggressive investors. CRISPR Therapeutics and its partner Vertex Pharmaceuticals have the only approved CRISPR therapy. Several other biotech ...
-2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with approximately $1.9 billion in cash, cash equivalents, and ...
Hosted on MSN1mon
The ethical and security implications of genetic engineeringIt underlines the necessity for comprehensive global governance to ensure the responsible and ethical use of genetic engineering technologies to mitigate risks and maximise benefits. Biotechnology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback